To Study the Safety and Pharmacokinetics of BLYG8824A in Patients with Locally Advanced or Metastatic Colorectal Cancers

2023-503409-12-00 Protocol GO41751 Human pharmacology (Phase I) - First administration to humans Ended

Start 26 Oct 2020 · End 17 Oct 2024 · Status Ended · 1 EU/EEA countries · 3 sites · Protocol GO41751

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 58
Countries 1
Sites 3

Locally Advanced or Metastatic Colorectal Cancers (mCRC)

Key facts

Sponsor
Genentech Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
26 Oct 2020 → 17 Oct 2024
Decision date (initial)
2024-07-30
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-503409-12-00
EudraCT number
2019-004874-24

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Locally Advanced or Metastatic Colorectal Cancers (mCRC)

VersionLevelCodeTermSystem organ class
27.0 PT 10052358 Colorectal cancer metastatic 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Genentech Inc.

Sponsor organisation
Genentech Inc.
Address
1 Dna Way
City
South San Francisco
Postcode
94080-4990
Country
United States

Scientific contact point

Organisation
Genentech Inc.
Contact name
US Program Manager Product Development Regulatory

Public contact point

Organisation
Genentech Inc.
Contact name
US Program Manager Product Development Regulatory

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 24 3
Rest of world
Australia, Canada, United States
34

Investigational sites

Spain

3 sites · Ended
Hospital Universitario Fundacion Jimenez Diaz
Medical Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Universitari Vall D Hebron
Medical Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Clinica Universidad De Navarra
Medical Oncology, Pio XII Etorbidea 36, 31008, Pamplona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2020-10-26 2020-11-02 2023-11-03

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-23 Spain Acceptable with conditions
2024-07-30
2024-07-30